SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/13/24 Sangamo Therapeutics, Inc. 10-K 12/31/23 96:41M Workiva Inc Wde… FA01/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.33M 2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 41K 3: EX-10.24 Material Contract HTML 45K 4: EX-10.35 Material Contract HTML 33K 5: EX-10.36 Material Contract HTML 33K 6: EX-21.1 Subsidiaries List HTML 27K 7: EX-23.1 Consent of Expert or Counsel HTML 29K 8: EX-31.1 Certification -- §302 - SOA'02 HTML 32K 9: EX-31.2 Certification -- §302 - SOA'02 HTML 32K 10: EX-32.1 Certification -- §906 - SOA'02 HTML 31K 16: R1 Cover HTML 94K 17: R2 Audit Information HTML 33K 18: R3 Consolidated Balance Sheets HTML 140K 19: R4 Consolidated Balance Sheets (Parenthetical) HTML 48K 20: R5 Consolidated Statements of Operations HTML 108K 21: R6 Consolidated Statements of Comprehensive Loss HTML 60K 22: R7 Consolidated Statements of Stockholders? Equity HTML 111K 23: R8 Consolidated Statements of Cash Flows HTML 137K 24: R9 Organization, Basis of Presentation and Summary of HTML 114K Significant Accounting Policies 25: R10 Fair Value Measurements HTML 88K 26: R11 Cash Equivalents and Marketable Securities HTML 92K 27: R12 Major Customers, Partnerships and Strategic HTML 129K Alliances 28: R13 Acquisition of Sangamo France HTML 34K 29: R14 Impairment of Goodwill, Indefinite-Lived HTML 42K Intangible Assets and Other Long-Lived Assets 30: R15 Other Balance Sheet Details HTML 65K 31: R16 Commitments and Contingencies HTML 55K 32: R17 Stockholders' Equity HTML 65K 33: R18 Stock-Based Compensation HTML 56K 34: R19 Restructuring Charges HTML 42K 35: R20 Employee Benefit Plan HTML 34K 36: R21 Income Taxes HTML 120K 37: R22 Subsequent Event HTML 32K 38: R23 Organization, Basis of Presentation and Summary of HTML 129K Significant Accounting Policies (Policies) 39: R24 Organization, Basis of Presentation and Summary of HTML 72K Significant Accounting Policies (Tables) 40: R25 Fair Value Measurements (Tables) HTML 85K 41: R26 Cash Equivalents and Marketable Securities HTML 88K (Tables) 42: R27 Major Customers, Partnerships and Strategic HTML 67K Alliances (Tables) 43: R28 Other Balance Sheet Details (Tables) HTML 68K 44: R29 Commitments and Contingencies (Tables) HTML 48K 45: R30 Stockholders' Equity (Tables) HTML 53K 46: R31 Stock-Based Compensation (Tables) HTML 57K 47: R32 Restructuring Charges (Tables) HTML 35K 48: R33 Income Taxes (Tables) HTML 121K 49: R34 ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF HTML 64K SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) 50: R35 ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF HTML 42K SIGNIFICANT ACCOUNTING POLICIES - Schedule of Revenues from Collaboration and Licensing Agreements (Details) 51: R36 ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF HTML 42K SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Accounts Receivable by Collaboration Partners (Details) 52: R37 ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF HTML 37K SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) 53: R38 Fair Value Measurements (Details) HTML 103K 54: R39 CASH EQUIVALENTS AND MARKETABLE SECURITIES - HTML 82K Schedule of Cash Equivalents and Marketable Securities (Details) 55: R40 CASH EQUIVALENTS AND MARKETABLE SECURITIES - HTML 36K Schedule of Fair Value of Marketable Securities by Contractual Maturity (Details) 56: R41 CASH EQUIVALENTS AND MARKETABLE SECURITIES - HTML 37K Narrative (Details) 57: R42 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 85K ALLIANCES - Pfizer Inc. (Narrative) (Details) 58: R43 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 85K ALLIANCES - Kite Pharma, Inc. (Narrative) (Details) 59: R44 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 57K ALLIANCES - Schedule of Revenues Recognized under Agreement (Details) 60: R45 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 52K ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Narrative) (Details) 61: R46 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 84K ALLIANCES - Biogen MA, Inc. (Narrative) (Details) 62: R47 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 83K ALLIANCES - Sanofi S.A. (Narrative) (Details) 63: R48 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 47K ALLIANCES - California Institute for Regenerative Medicine (Narrative) (Details) 64: R49 MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC HTML 60K ALLIANCES - Agreement with Sigma-Aldrich Corporation (Narrative) (Details) 65: R50 Acquisition of Sangamo France (Details) HTML 45K 66: R51 Impairment of Goodwill, Indefinite-Lived HTML 53K Intangible Assets and Other Long-Lived Assets (Details) 67: R52 OTHER BALANCE SHEET DETAILS - Schedule of Property HTML 48K and Equipment, Net (Details) 68: R53 OTHER BALANCE SHEET DETAILS - Narrative (Details) HTML 46K 69: R54 OTHER BALANCE SHEET DETAILS - Schedule of HTML 50K Intangible Assets and Goodwill (Details) 70: R55 OTHER BALANCE SHEET DETAILS - Schedule of Other HTML 44K Accrued Liabilities (Details) 71: R56 COMMITMENTS AND CONTINGENCIES - Narrative HTML 89K (Details) 72: R57 COMMITMENTS AND CONTINGENCIES - Schedule of HTML 35K Components of Operating Leases (Details) 73: R58 COMMITMENTS AND CONTINGENCIES - Schedule of Future HTML 56K Minimum Payments under Lease Obligations (Details) 74: R59 STOCKHOLDERS' EQUITY - Narrative (Details) HTML 142K 75: R60 STOCKHOLDERS' EQUITY - Schedule of Stock Option HTML 68K Activity (Details) 76: R61 STOCKHOLDERS' EQUITY - Schedule of Restricted HTML 46K Stock Unit Activity (Details) 77: R62 STOCK-BASED COMPENSATION - Schedule of Stock-Based HTML 36K Compensation Expense (Details) 78: R63 STOCK-BASED COMPENSATION - Narrative (Details) HTML 55K 79: R64 STOCK-BASED COMPENSATION - Schedule of Assumptions HTML 52K used for Estimating Fair Value of Employee Stock Options (Details) 80: R65 STOCK-BASED COMPENSATION - Schedule of Assumptions HTML 52K used for Estimating the Fair Value of the ESPP Purchase Rights (Details) 81: R66 RESTRUCTURING CHARGES - Narrative (Details) HTML 88K 82: R67 RESTRUCTURING CHARGES - Schedule of Accrued HTML 38K Restructuring Costs (Details) 83: R68 Employee Benefit Plan (Details) HTML 34K 84: R69 INCOME TAXES - Schedule of Domestic and Foreign HTML 38K Components of Loss Before Income Taxes (Details) 85: R70 INCOME TAXES - Schedule of Income Tax Expense HTML 54K (Benefit) (Details) 86: R71 INCOME TAXES - Schedule of Difference Between HTML 54K Income Tax Expense (Benefit) and Federal Statutory Income Tax Rate to Loss Before Income Taxes (Details) 87: R72 INCOME TAXES - Schedule of Deferred Tax Assets and HTML 67K Liabilities (Details) 88: R73 INCOME TAXES - Schedule of Deferred Tax Assets and HTML 37K Liabilities Based on Tax Jurisdictions (Details) 89: R74 INCOME TAXES - Narrative (Details) HTML 59K 90: R75 INCOME TAXES - Schedule of Unrecognized Tax HTML 38K Benefits (Details) 91: R76 Subsequent Event (Details) HTML 50K 93: XML IDEA XML File -- Filing Summary XML 182K 96: XML XBRL Instance -- sgmo-20231231_htm XML 2.35M 92: EXCEL IDEA Workbook of Financial Report Info XLSX 204K 12: EX-101.CAL XBRL Calculations -- sgmo-20231231_cal XML 246K 13: EX-101.DEF XBRL Definitions -- sgmo-20231231_def XML 894K 14: EX-101.LAB XBRL Labels -- sgmo-20231231_lab XML 1.87M 15: EX-101.PRE XBRL Presentations -- sgmo-20231231_pre XML 1.35M 11: EX-101.SCH XBRL Schema -- sgmo-20231231 XSD 223K 94: JSON XBRL Instance as JSON Data -- MetaLinks 542± 860K 95: ZIP XBRL Zipped Folder -- 0001628280-24-010788-xbrl Zip 12.43M
exhibit1024incentivecomp |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/13/24 | None on these Dates | ||
For Period end: | 12/31/23 | |||
10/16/23 | ||||
10/2/23 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/24 Sangamo Therapeutics, Inc. 424B5 1:3M Donnelley … Solutions/FA |